Investment Rating - The industry investment rating is "Overweight" (maintained) [1] Core Views - The insurance sector has seen a 15.7% increase since December 5, outperforming the CSI 300 index, which increased by 0.5% [4] - The release of the asset-liability management measures for insurance companies is expected to enhance regulatory oversight and impact asset allocation and insurance operations, particularly for small and medium-sized insurers [5] - The brokerage sector is anticipated to benefit from a positive regulatory environment, with potential growth in investment banking, public funds, and overseas business, supporting profitability in 2026 [6] Summary by Sections Insurance Sector - The new asset-liability management measures aim to strengthen the linkage between assets and liabilities, with implementation starting on July 1, 2026 [5] - Key management goals include matching duration structures, cost-benefit alignment, and liquidity matching [5] - The transition to dividend insurance is expected to deepen, with a favorable settlement yield compared to traditional insurance, driven by increased demand for savings products [5] - Long-term interest rates stabilizing and a positive equity market outlook are expected to improve net assets and profitability for insurers [5] Brokerage Sector - The average daily trading volume for stock funds is 2.2 trillion, reflecting a 7.2% decrease [6] - The resumption of trading for China International Capital Corporation (CICC) has led to a rise in stock prices, with expectations of increased leverage and business synergy [6] - The brokerage sector remains undervalued, with strategic opportunities for investment in firms with strong overseas and institutional business advantages [6] - Recommended stocks include Huatai Securities, Guotai Junan, and CICC, among others [6]

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The biopharmaceutical investment and financing environment has shown significant recovery since the second half of 2025, with a total financing amount of USD 30.32 billion from July to November 2025, representing a year-on-year increase of 30.90% [4] - The number of new drug IND applications stabilized in 2025, with approximately 1,897 applications from January to November, reflecting a year-on-year growth of about 7.91% [4] - The demand for CRO services has shown a clear turning point, and the report continues to recommend opportunities in the innovative drug industry chain (CXO + research services) for 2026 [4] Summary by Sections Industry Performance - The biopharmaceutical sector experienced a decline of 0.14% in the third week of December 2025, outperforming the CSI 300 index by 0.14 percentage points, ranking 22nd among 31 sub-industries [7][14] - The offline pharmacy sector saw the highest increase, rising by 5.59%, while the chemical preparation sector had the largest decline at 2.1% [18][22] Investment Opportunities - The report highlights the strong performance of leading CXO and research service companies, with many exceeding earnings expectations. Companies like WuXi AppTec and Tigermed have raised their earnings guidance for 2025 [5] - The report recommends a valuation switch opportunity for leading CXO and research service companies, given the continuous improvement in demand [5] Clinical Research Organizations (CRO) - There has been a notable improvement in orders for preclinical and clinical CROs, with expectations for significant improvements in financial statements for 2026 [6] - The report anticipates that the market demand will continue to focus on leading companies as the capacity of clinical CROs is expected to be streamlined [6] Monthly and Weekly Recommendations - The report recommends a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drug opportunities and valuation switch [8]

金融工程专题 2025 年 12 月 21 日 金融工程研究团队 魏建榕（首席分析师） 证书编号：S0790519120001 傅开波（分析师） 证书编号：S0790520090003 高 鹏（分析师） 证书编号：S0790520090002 苏俊豪（分析师） 证书编号：S0790522020001 胡亮勇（分析师） 证书编号：S0790522030001 王志豪（分析师） 证书编号：S0790522070003 盛少成（分析师） 证书编号：S0790523060003 我们在专题报告《大单与小单资金流的 alpha 能力》中，对日度资金流信息进行 了标准化和动量中性化两步处理，构造得到了大单和小单资金流残差因子。日度 资金流残差因子选股效果优异，样本外选股效果相对稳健。本文参考日度资金流 残差因子的构造思路，以逐笔成交数据合成得到的分钟资金流信息为对象，提供 三类分钟资金流因子的构造方法。 蒋 韬（分析师） 证书编号：S0790525070001 相关研究报告 《大小单资金流为核心的综合行业轮 动方案—市场微观结构系列（23）》 -2024.1.28 《大小单资金流 alpha 探究 2.0：变量 精筛与高 ...

食品饮料 2025 年 12 月 21 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -14% -7% 0% 7% 14% 22% 29% 2024-12 2025-04 2025-08 食品饮料 沪深300 相关研究报告 《中央经济工作会议积极定调，飞天 批价或止跌触底 — 行 业 周 报 》 -2025.12.14 开 源 证 券 证 券 研 究 报 告 《白酒短期批价扰动，西麦新品值得 关注—行业周报》-2025.12.7 《茅台韧性凸显，建议长期配置布局 —行业周报》-2025.11.30 消费筑底政策共振，白酒或至底部重视布局 ——行业周报 张宇光（分析师） 张思敏（分析师） zhangyuguang@kysec.cn 证书编号：S0790520030003 zhangsimin@kysec.cn 证书编号：S0790525080001 核心观点：内需政策赋能消费，白酒进入深度调整期 12 月 15 日-12 月 19 日，食品饮料指数涨幅为 1.0%，一级子行业排名第 11，跑 赢沪深 300 约 1.3pct，子行业中烘焙食品（+8.0%）、零食（+7.5%）、预加工食 品（+5.6% ...

Group 1 - The report highlights the performance of the North Exchange in 2025, indicating a significant rise in the North Index 50 to around 1400 points, with three distinct phases of market movement: rapid increase, oscillating rise, and a correction phase [2][12][15] - In the rapid increase phase (January 1 - March 11, 2025), the North Index 50 surged from 1,037.81 to 1,418.65 points, achieving a cumulative return of 36.70%, while the specialized index rose from 1,683.33 to 2,421.50 points, with a return of 43.85% [15][16] - The oscillating rise phase (April 7 - September 5, 2025) saw the North Index 50 increase from 1,044.07 to 1,647.01 points, yielding a cumulative return of 58.70%, and the specialized index from 1,759.64 to 2,806.39 points, with a return of 66.72% [16][17] Group 2 - The correction phase (September 15 - December 19, 2025) stabilized the North Index 50 and specialized index around 1400 and 2400 points, respectively, with the North Index 50 declining to 1,445.84 points and the specialized index to 2,440.21 points, resulting in cumulative returns of 39.32% and 44.96% [17][23] - The report emphasizes the performance of small-cap stocks, indicating that companies with market capitalizations of 0-20 billion, 20-40 billion, 40-80 billion, and above 80 billion had average returns of 54.08%, 38.60%, 18.26%, and 30.59%, respectively [26][31] - The report identifies that national and provincial-level "little giant" companies outperformed non-little giant firms, with average returns of 48.26%, 38.06%, and 39.19% for national, provincial, and non-little giants, respectively [27][29] Group 3 - The report highlights that national and provincial-level single champion companies achieved average returns of 59.27% compared to 39.61% for non-single champion companies [32][34] - In terms of industry performance, high-end equipment and new chemical materials sectors showed higher returns, with average returns of 50.20%, 28.67%, 48.49%, 40.43%, and 43.56% for high-end equipment, information technology, new chemical materials, consumer services, and biomedicine, respectively [34][36] - The report also notes that companies with new productive forces, ESG attributes, high scarcity, and high dividends had average returns of 50.49%, 48.44%, 49.14%, and 57.51%, respectively, indicating a strong performance in these categories [37][43]

北交所策略专题报告 2025 年 12 月 21 日 我国首批 L3 级自动驾驶准入获批，关注北证传感器及智慧交通链 ——北交所策略专题报告 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 我国首批 L3 级自动驾驶准入许可获批，关注北证智驾和车路云标的 2025 年 12 月 15 日，工业和信息化部正式公布我国首批 L3 级自动驾驶车型准入 许可。北交所内汽车相关标的共有 31 家，包含开特股份、林泰新材、苏轴股份、 大鹏工业、奥迪威、吉冈精密、骏创科技、巴兰仕、九菱科技、明阳科技、华原 股份、旺成科技、邦德股份、易实精密、捷众科技、三祥科技、威贸电子、建邦 科技、舜宇精工、华洋赛车、世昌股份、安徽凤凰、大地电气、同心传动、天铭 科技、浩淼科技、泰德股份、智新电子、华阳变速、德众汽车。智慧城市、智慧 交通方面则有标的 8 家，包含云星宇、路桥信息、汉鑫科技、广脉科技、天润科 技、科达自控、立方控股、微创光电。关注奥迪威、汉鑫科技等。奥迪威（920491.BJ） 自主研发的新一代 AKII 车载超声波传感器，满足智驾系统的升级和行泊一体技 术的 ...

Group 1 - The core viewpoint of the report indicates that the leading carbon fiber companies are raising prices, with high-end product demand expected to recover first. Toray announced a price increase of 10%-20% for its TORAYCA™ carbon fiber products starting January 2026, while Jilin Chemical Fiber plans to raise prices by 5,000 RMB and 10,000 RMB per ton for its 12TK and 3K carbon fibers respectively, also effective January 2026 [1][10] - The current carbon fiber market shows a clear differentiation, with general and large tow products facing strong competition, while high-performance products have stabilized in price, with some specifications experiencing tight supply and demand [1][10] - The report highlights that the carbon fiber industry in China is expected to continue expanding, with production capacity projected to reach 135,500 tons by 2024, and a production volume of approximately 59,000 tons, reflecting an 8.2% year-on-year growth [16][17] Group 2 - The report notes that the chemical new materials sector on the North Exchange has seen a weekly increase of 2.53%, with the metal new materials segment performing particularly well, rising by 11.31% [3][30] - Jilin Carbon Valley has established itself as a major player in the carbon fiber market, with a full range of products from small to large tow fibers, and has achieved stable large-scale production of high-quality products [2][27] - The report provides insights into the performance of individual stocks within the chemical new materials sector, with notable increases in stock prices for Tianli Composite (+41.42%), Jilin Carbon Valley (+9.17%), and others [34][37] Group 3 - The report includes a detailed analysis of chemical product price trends, highlighting fluctuations in prices for various materials such as MDI, TDI, and natural rubber, with MDI priced at 18,900 RMB per ton and TDI at 14,800 RMB per ton [38] - The carbon fiber demand distribution in China for 2023 shows that the top three application areas are sports and leisure (26.1%), wind power blades (24.6%), and aerospace and military (11.6%) [20][21] - The report emphasizes the strategic investments by companies like Hechang Polymer, which aims to enhance resource integration and business synergy through the introduction of strategic investors [4][66]

Group 1 - The brain-computer interface (BCI) is recognized as a future industry in China's 14th Five-Year Plan, with policies aimed at fostering its development, including a target for core technology breakthroughs by 2027 and achieving global leadership by 2030 [3][12][16] - The global BCI market was valued at $1.5 billion in 2021 and is projected to reach $3.3 billion by 2027, while the domestic market is expected to grow from 3.2 billion yuan in 2024 to 4.6 billion yuan by 2026, reflecting an 18.81% year-on-year growth in 2024 [3][17][19] - Non-invasive BCIs dominate the market, accounting for 86% of the total, with medical applications being the primary focus, representing 56% of the downstream enterprises [18][23][25] Group 2 - The 2024 national pharmaceutical circulation market is projected to reach 2.947 trillion yuan, with the wholesale market accounting for 77.94% of total sales, and the retail market contributing 22.06% [4][40][46] - The pharmaceutical distribution industry is characterized by a continuous optimization of structure, enhanced professional service capabilities, and a growing focus on health services, driven by aging populations and increased health awareness [52][53] - The North Exchange has 11 listed companies related to pharmaceuticals, with significant profit margins reported, including companies like Deyuan Pharmaceutical and Xinghao Pharmaceutical, which have shown substantial growth in net profits [4][51][68] Group 3 - The North Exchange's pharmaceutical and biotechnology sector saw a weekly increase of 1.91%, with medical devices leading the growth at 6%, while 80.95% of the sector's stocks experienced an increase in market value [5][58][61] - Notable stock performances include Lude Medical and Beiyikang, which saw weekly increases of 20.61% and 10.46%, respectively, indicating strong market interest in these companies [5][67] - As of December 19, 2025, there are 13 pharmaceutical and biotechnology companies queued for listing on the North Exchange, with an average revenue of 382 million yuan and net profits exceeding 100 million yuan for several firms [68][69]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The retail industry index rose by 6.66% in the week of December 15-19, 2025, outperforming the Shanghai Composite Index by 6.63 percentage points, ranking first among 31 primary industries [6][15] - The launch of the Hainan Free Trade Port has shown promising initial results, with duty-free sales reaching 118 million yuan on the first day and a significant increase in the number of zero-tariff goods [4][25][26] - The report emphasizes the importance of consumer sentiment and the potential for high-growth sectors within the retail space, particularly in jewelry, offline retail, cosmetics, and medical aesthetics [7][30][31] Summary by Sections Retail Market Review - The retail industry index closed at 2458.79 points, with a weekly increase of 6.66% [6][15] - The supermarket sector saw the highest weekly increase of 14.18%, while the commercial property sector led with a year-to-date increase of 22.51% [17][19] Industry Dynamics - The Hainan Free Trade Port officially commenced operations on December 18, 2025, with a focus on "one line open, two lines controlled, and free trade within the island" [4][25] - The proportion of zero-tariff goods increased from 21% to 74%, covering approximately 6,600 items, which is expected to reduce import tax burdens by about 20% for related enterprises [26][25] Investment Themes - Investment Theme 1: Focus on high-end jewelry brands with differentiated product offerings, recommending companies like Chow Tai Fook and Lao Pu Gold [7][30] - Investment Theme 2: Emphasize offline retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiying Room [7][30] - Investment Theme 3: Highlight domestic cosmetics brands that meet emotional value and safety ingredient innovations, recommending brands like Maogeping and Proya [7][31] - Investment Theme 4: Focus on differentiated medical aesthetics product manufacturers and leading chain medical institutions, recommending Aimeike and Kedi-B [7][31] Company-Specific Insights - Chow Tai Fook reported a revenue of 38.986 billion HKD for FY2026H1, with a slight decline of 1.1% year-on-year, while net profit increased by 0.1% [37] - Lao Pu Gold achieved a revenue of 12.354 billion HKD for FY2025H1, marking a significant increase of 250.9% year-on-year, with net profit rising by 285.8% [36] - Yonghui Supermarket's revenue for the first three quarters of 2025 was 42.434 billion yuan, down 22.2% year-on-year, with net profit showing a significant loss [44]

Investment Rating - Industry investment rating: Positive (maintained) [1] Core Views - The report highlights the potential recovery in fiber optic cable prices driven by increased demand from AI applications and the acceleration of domestic AI bidding processes [6][19] - The AI ecosystem is continuously evolving, with significant advancements in models and infrastructure, particularly from major players like ByteDance and Google [15][16] - The demand for fiber optic cables is expected to rise due to the increasing requirements for internal network connectivity in AI model training and application deployment [18] Summary by Sections 1. Weekly Investment Insights - The opening of the Volcano Engine FORCE conference showcased advancements in AI agent technology and cloud-native architecture [13] - The daily token usage of the Doubao model has surpassed 50 trillion, indicating rapid industry adoption [15] - Google is enhancing its AI ecosystem, with new TPU chips expected to drive demand for liquid cooling solutions [16] - Companies are increasingly interested in renting TPU chips, which will further stimulate ASIC demand [17] - AI is driving the demand for fiber optic cables, with prices expected to recover [18] - Investment recommendations focus on key sectors such as optical networks, liquid cooling, and domestic computing power [19] 2. Communication Data Tracking - As of October 2025, the total number of 5G base stations in China reached 4.758 million, with a net increase of 507,000 from the end of 2024 [28] - The number of 5G mobile phone users reached 1.184 billion, reflecting a year-on-year growth of 18.99% [28] - The shipment of 5G mobile phones in September 2025 was 24.106 million units, representing an 8.02% year-on-year increase [28] 3. Operator Performance - The revenue from cloud services for major operators showed strong growth, with China Mobile's cloud revenue reaching 56.1 billion yuan, up 11.3% year-on-year [47] - China Telecom's cloud revenue for the first half of 2025 was 57.3 billion yuan, a 3.8% increase [47] - The ARPU values for major operators remained stable, with slight decreases noted for China Unicom [47][52]